Last updated: April 24, 2026
AU2007230716: What Is Covered, How Broad the Claims Are, and Where It Sits in the Australia Patent Landscape
What is AU2007230716 and who owns it?
AU2007230716 is an Australian patent application/publication filed in 2007. It is listed in the Australian patent register under the publication family AU2007230716 (IP Australia). The document’s scope and claim structure should be assessed against three layers that determine commercial reach in Australia:
1) Claim language (independent and dependent claims) defining the covered subject matter
2) Enabling disclosure (examples, assays, formulations, and claimed ranges) that constrain claim interpretation
3) Relationship to counterpart filings (often US, EP, or WO) that affect claim breadth through prosecution history and claim amendments
Result: Without the patent text (claims) and bibliographic data (applicant, priority, CPC/IPC, and legal status), a complete and accurate scope-and-claims analysis for AU2007230716 cannot be produced.
What is the claim scope and how broad is it?
A claim-scope analysis requires the actual independent claims, because that is where coverage is typically defined by:
- Active ingredient(s) or Markush-defined chemical structures
- Formulation type (e.g., solid oral dose vs injectable vs transdermal)
- Therapeutic use (medical indication)
- Dosing regimens (dose ranges, schedules)
- Manufacturing process steps (if product-by-process is claimed)
A complete “breadth” assessment also requires:
- Whether claims are compound claims, use claims, formulation claims, or process claims
- Whether compounds are defined by explicit structure vs genus/Markush
- Whether functional language is used (for example “inhibits,” “treats,” “capable of,” “pharmaceutically acceptable”) and how narrowly the specification supports it
- Whether claim limitations are tied to assays and thresholds
Result: The claims themselves are not present in the prompt, so breadth and scope cannot be determined in a way that meets a high-stakes R&D or investment standard.
Where does AU2007230716 sit in the Australia patent landscape?
Landscape positioning for an Australian drug filing typically turns on:
- Active ingredient identity (or target pathway) and whether it aligns with a known marketed product or a late-stage pipeline
- Priority date and remaining term in Australia (20 years from the earliest priority, with PTA-like effects only in limited contexts)
- Patent family coverage (other jurisdictions and whether Australia has the broadest or narrowest claim set)
- Interference with freedom-to-operate (how many later filings reference the same API/indication/formulation)
- Regulatory exclusivities that interact with patent enforcement risk (TGA marketing approval pathways)
To map this properly for AU2007230716, the analysis must identify:
- The active ingredient(s) and therapeutic indication(s) claimed
- The earliest priority and whether any continuations/divisionals exist in Australia
- Whether there are later Australian patents from the same family that add formulation or method-of-use breadth
- Whether generic/biosimilar challengers have filed Australian patent challenges (common mechanisms include revocation proceedings, or “notices of contention” in some contexts)
Result: Landscape mapping requires the patent’s technical subject matter and bibliographic/legal status, none of which are included in the prompt.
What cannot be stated from the provided input
A complete, accurate response must include at least:
- Applicants/assignees
- Priority data
- Independent claim text
- Claim chart style breakdown (claim elements, ranges, and dependent claim variations)
- Cited documents and prosecution equivalents across the family
- Specific in-Australia citations (other AU grants/publications that overlap)
The input contains only the identifier AU2007230716 and does not include the patent document content required to perform those elements without inventing facts.
Key Takeaways
- AU2007230716 cannot be analyzed for scope, claims, and landscape position to the standard required for R&D or investment decisions without the underlying patent text and bibliographic/legal data.
- Any attempt to describe claim breadth, therapeutic reach, or landscape overlap without the claims would risk fabricating coverage.
- A valid analysis must be claim-driven and family-driven (priority, equivalents, and Australian legal status).
FAQs
-
Can you determine AU2007230716’s claim scope without the claims text?
No. Claim breadth depends on the exact independent claim language and dependent limitations.
-
How do you measure “breadth” for Australian drug patents?
By comparing independent claim structure (compound vs use vs formulation vs process), definition style (explicit structure vs Markush/genus), and support for functional language and ranges in the specification.
-
What matters most for freedom-to-operate in Australia for drug patents?
The covered API/indication/formulation elements in independent claims, plus any later family members that extend coverage, and the enforcement posture in Australia.
-
How does the priority date control exclusivity in Australia?
The baseline term runs from the earliest priority date (20 years), and the enforceable scope depends on the final claim set in the Australian publication/grant.
-
What does “landscape” mean in patent analysis for drugs?
It means mapping overlapping patents in Australia (same API/target/indication/formulation), family equivalents across jurisdictions, and procedural/legal events that affect enforceability.
References
[1] IP Australia. Australian Patents Register. Publication: AU2007230716. (Source identifier only; patent text and bibliographic/claims content not provided in the prompt.)
